期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 63, 期 7, 页码 713-719出版社
SPRINGER
DOI: 10.1007/s00262-014-1521-3
关键词
CIMT 2013; Immunocompetence; Immune monitoring; Mass cytometry
资金
- NCI NIH HHS [P30 CA124435] Funding Source: Medline
- NIAID NIH HHS [U19 AI057229, U19 AI090019] Funding Source: Medline
A new era of cancer immunotherapy has brought not only successful cancer vaccines but also immunomodulators, such as those that target checkpoint blockade in order to induce endogenous host immune responses. However, the immune system of cancer patients can be compromised through multiple means, including immune suppression by the tumor and by prior therapies such as chemotherapy and radiation. Therefore, a comprehensive means of assessing patient immunocompetence would seem helpful for determining whether patients are ready to benefit from immunotherapy, and perhaps even which immunotherapy might be most appropriate for them. Unfortunately, there are no standardized tests for immune competence, nor is there agreement on what to measure and what will be predictive of outcome. In this review, we will discuss the technologies and assays that might be most useful for this purpose. We argue for a comprehensive approach that should maximize the chances of developing predictive biomarkers for eventual clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据